SSShuai Shao

Shuai Shao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shuai Shao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Fu Jie Shen

    The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, China

    1 shared publication
  • Hao Zhang

    The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, China

    1 shared publication
  • Ji Guo Su

    The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, China

    1 shared publication
  • Jing Zhang

    The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, China

    1 shared publication
  • Jun Wei Hou

    The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, China

    1 shared publication
  • Li Fang Du

    The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing 101111, China

    1 shared publication

Latest Publications

  • Mutating a flexible region of the RSV F protein can stabilize the prefusion conformation

    by Yu Liang, Shuai Shao, Xin Yu Li, Zi Xin Zhao, Ning Liu, Zhao Ming Liu, Fu Jie Shen, Hao Zhang, Jun Wei Hou, Xue Feng Zhang, et al.

    The respiratory syncytial virus (RSV) fusion (F) glycoprotein is highly immunogenic in its prefusion (pre-F) conformation. However, the protein is unstable, and its conformation must be stabilized for it to function effectively as an immunogen in vaccines. We present a mutagenesis strategy to arrest the RSV F protein in its pre-F state by blocking localized changes in protein structure that accompany large-scale conformational rearrangements. We generated a series of mutants and screened them in vitro to assess their potential for forming a stable pre-F. In animals, the immunogenicity of a representative mutant F protein, with a conformation confirmed by cryo–electron microscopy, elicited levels of neutralizing antibodies and protection against RSV-induced lung damage that were comparable to those of DS-Cav1, a pre-F used in a licensed vaccine.